Drug intelligence / Profile preview

IRL942

Development stage: Preclinical
Lead developer: Integrative Research Laboratories Sweden AB
Modality: Small Molecules

Overview

IRL942 is a preclinical-stage small molecule candidate developed by IRLAB Therapeutics for the treatment of cognitive dysfunction associated with Parkinson's disease and other neurological disorders. It is part of IRLAB's neuropsychiatric pipeline and was the subject of an evaluation agreement with the McQuade Center for Strategic Research and Development (MSRD), an affiliate of Otsuka, in May 2023. The compound aims to address cognitive impairment, a significant non-motor symptom in neurodegenerative conditions, by potentially modulating neurotransmitter systems involved in frontal lobe function.

Beyond the preview

Go deeper on IRL942.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRL942.

Explore the full profile